Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 15/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 15/20 | 0.53 |
| ▸ | EIF4E | P06730 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22228903 | 1.00 | CCNT1 (0.55) | CCNT1FLT3CDK9MKNK1MKNK2 | |
| SCHEMBL22228724 | 0.87 | CCNT1 (0.54) | CCNT1FLT3CDK9MKNK1MKNK2 | |
| SCHEMBL31501006 | 0.87 | CCNT1 (0.54) | CCNT1FLT3CDK9MKNK1MKNK2 | |
| SCHEMBL22228878 | 0.82 | CDK9 (0.79) | CCNT1FLT3CDK9MKNK1MKNK2 | |
| SCHEMBL31500961 | 0.82 | CDK9 (0.79) | CCNT1FLT3CDK9MKNK1MKNK2 | |
| SCHEMBL22228834 | 0.81 | CDK9 (0.65) | CCNT1FLT3CDK9MKNK1MKNK2 | |
| SCHEMBL22228837 | 0.81 | CDK9 (0.65) | CCNT1FLT3CDK9MKNK1MKNK2 | |
| SCHEMBL20455550 | 0.79 | FLT3 (0.62) | CCNT1FLT3CDK9IRAK4 | |
| SCHEMBL22228742 | 0.79 | CDK9 (0.67) | CCNT1FLT3CDK9MKNK1MKNK2 | |
| SCHEMBL22252924 | 0.79 | CDK9 (0.67) | CCNT1FLT3CDK9MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3577116-B1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-A]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | CHANGZHOU QIANHONG BIO PHARMA CO LTD (CN) | 2025-04-23 | — | — | EP | disclosed |
| US-11111245-B2 | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-09-07 | — | — | US | disclosed |
| US-20200231586-A1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231586-A1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | CDK2, CDKL1, CDKL2 | CCNT1 52/4885FLT3 282/4885CDK9 7/4885 |
| US-11111245-B2 | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents | CDK2, CDKL1, CDKL2 | CCNT1 52/4885FLT3 282/4885CDK9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.